Key statistics
As of last trade Fagron NV (4A5:FRA) traded at 22.60, -3.00% below its 52-week high of 23.30, set on Feb 13, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 22.60 |
|---|---|
| High | 22.60 |
| Low | 22.60 |
| Bid | 22.50 |
| Offer | 22.60 |
| Previous close | 23.30 |
| Average volume | 131.71 |
|---|---|
| Shares outstanding | 73.67m |
| Free float | 56.70m |
| P/E (TTM) | -- |
| Market cap | 1.68bn EUR |
| EPS (TTM) | -- |
| Annual div (ADY) | 0.35 EUR |
|---|---|
| Annual div yield (ADY) | 1.50% |
| Div ex-date | May 19 2025 |
| Div pay-date | May 21 2025 |
Data delayed at least 15 minutes, as of Feb 16 2026 07:12 GMT.
More ▼
Announcements
- Fagron behoudt uitstekende prestaties in boekjaar 2025 met 9,2% omzetgroei en een stijging van de REBITDA met 10,9%
- Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA
- Fagron obtains regulatory clearance for the acquisition of Vepakum in Brazil and completes the acquisition of Magilab in Hungary
- Fagron verkrijgt goedkeuring van lokale autoriteiten voor de overname van Vepakum in Brazilië en rondt de overname van Magilab in Hongarije af
- Voorkennis: Fagron kondigt de afronding van de overname van University Compounding Pharmacy in Noord-Amerika aan
- Inside information: Fagron announces the completion of the acquisition of University Compounding Pharmacy in North America
- Openbaarmaking van kennisgeving ontvangen van BNP Paribas
- Disclosure of notification received from BNP Paribas
- Fagron announces the completion of Purifarma
- Fagron kondigt de afronding van de overname van Purifarma aan
More ▼
